Corbus Pharmaceuticals Holdings Inc. [NASDAQ: CRBP] jumped around 0.16 points on Thursday, while shares priced at $1.38 at the close of the session, up 13.11%. The company report on November 12, 2020 that Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference.
Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM EST.
Corbus Pharmaceuticals Holdings Inc. stock is now -74.73% down from its year-to-date (YTD) trading value. CRBP Stock saw the intraday high of $1.58 and lowest of $1.20 per share. The company’s 52-week high price is 9.78, which means current price is +51.65% above from all time high which was touched on 08/31/20.
Compared to the average trading volume of 5.14M shares, CRBP reached a trading volume of 12877386 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Corbus Pharmaceuticals Holdings Inc. [CRBP]?
ROTH Capital have made an estimate for Corbus Pharmaceuticals Holdings Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 08, 2020. The new note on the price target was released on September 08, 2020, representing the official price target for Corbus Pharmaceuticals Holdings Inc. stock. Previously, the target price had yet another drop from $18 to $2.50, while Jefferies kept a Hold rating on CRBP stock.
The Average True Range (ATR) for Corbus Pharmaceuticals Holdings Inc. is set at 0.11, with the Price to Sales ratio for CRBP stock in the period of the last 12 months amounting to 15.66. The Price to Book ratio for the last quarter was 2.09, with the Price to Cash per share for the same quarter was set at 0.78.
How has CRBP stock performed recently?
Corbus Pharmaceuticals Holdings Inc. [CRBP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.12. With this latest performance, CRBP shares gained by 24.89% in over the last four-week period, additionally sinking by -79.90% over the last 6 months – not to mention a drop of -67.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRBP stock in for the last two-week period is set at 60.22, with the RSI for the last a single of trading hit 71.26, and the three-weeks RSI is set at 40.10 for Corbus Pharmaceuticals Holdings Inc. [CRBP]. The present Moving Average for the last 50 days of trading for this stock 1.7372, while it was recorded at 1.2340 for the last single week of trading, and 5.3329 for the last 200 days.
Corbus Pharmaceuticals Holdings Inc. [CRBP]: Deeper insight into the fundamentals
Corbus Pharmaceuticals Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.10.
Earnings analysis for Corbus Pharmaceuticals Holdings Inc. [CRBP]
With the latest financial reports released by the company, Corbus Pharmaceuticals Holdings Inc. posted -0.41/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -13.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRBP.
Insider trade positions for Corbus Pharmaceuticals Holdings Inc. [CRBP]
There are presently around $83 million, or 75.60% of CRBP stock, in the hands of institutional investors. The top three institutional holders of CRBP stocks are: STATE STREET CORP with ownership of 16,618,149, which is approximately 445.558% of the company’s market cap and around 1.77% of the total institutional ownership; BLACKROCK INC., holding 5,903,239 shares of the stock with an approximate value of $8.15 million in CRBP stocks shares; and KNOLL CAPITAL MANAGEMENT, LP, currently with $6.96 million in CRBP stock with ownership of nearly 0% of the company’s market capitalization.
76 institutional holders increased their position in Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] by around 24,690,256 shares. Additionally, 50 investors decreased positions by around 2,889,387 shares, while 28 investors held positions by with 32,783,078 shares. The mentioned changes placed institutional holdings at 60,362,721 shares, according to the latest SEC report filing. CRBP stock had 27 new institutional investments in for a total of 2,954,098 shares, while 20 institutional investors sold positions of 918,922 shares during the same period.